Oppenheimer Maintains Madrigal Pharmaceuticals(MDGL.US) With Buy Rating, Cuts Target Price to $350
Madrigal Pharmaceuticals (MDGL) Gets a Buy From Oppenheimer
Express News | Madrigal Pharmaceuticals Inc : Oppenheimer Cuts Target Price to $350 From $375
H.C. Wainwright Maintains Madrigal Pharmaceuticals(MDGL.US) With Buy Rating, Maintains Target Price $390
Madrigal Pharmaceuticals' Promising Outlook: Buy Rating for Rezdiffra Amidst Enthusiastic Trial Enrollment and Regulatory Milestones
Express News | Madrigal Pharmaceuticals Completes Enrollment of Clinical Outcomes Study of Resmetirom in Patients With Compensated Nash/Mash Cirrhosis